PMID- 36161437
OWN - NLM
STAT- MEDLINE
DCOM- 20221108
LR  - 20221206
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Linking)
VI  - 35
IP  - 11
DP  - 2022 Nov
TI  - Cutaneous T cell lymphoma treated with mogamulizumab monotherapy and 
      mogamulizumab plus etoposide combined therapy: A real-world case series.
PG  - e15858
LID - 10.1111/dth.15858 [doi]
AB  - Since the efficacy of mogamulizumab has been confirmed by a phase III, randomized 
      study, mogamulizumab is one of the promising first-line therapies for advanced 
      cutaneous T cell lymphoma (CTCL), though its efficacy is not completely 
      satisfactory. Therefore, several anti-lymphoma drugs such as etoposide were 
      recently used to enhance the anti-tumor effects of mogamulizumab for the 
      treatment of mycosis fungoides (MF). In this report, the anti-tumor effects of 
      mogamulizumab and post mogamulizumab therapy were retrospectively evaluated in 11 
      cases of CTCL in real-world clinical practice. The best response rate (RR) was 
      45.5% (95% confidence interval [CI], 21.3%-72.0%) for the total cohort, 50.0% 
      (95%CI, 21.5%-78.5%) for the MF cohort, and 33.3% (95%CI, 5.6%-79.8%) for the 
      primary cutaneous peripheral T cell lymphoma not otherwise specified (PCPTCL-NOS) 
      cohort. The objective response rate (ORR) at 1 month (ORR1) for the total cohort 
      was 45.5% (95%CI, 21.3%-72.0%), and ORR at 4 months (ORR4) was 27.3% (95%CI, 
      9.2%-57.1%). The mean time to next treatment (TTNT) was 16.0 weeks (3-100 weeks) 
      for all patients, 16.5 months (3-100 weeks) for the MF cohort, and 9.0 (7-16) 
      weeks for the PCPTCL-NOS cohort. The efficacy rate of etoposide-based therapy was 
      71.4% (95%CI, 35.9%-98.0%) for all patients, 80% (95%CI, 35.9%-98.0%) in the MF 
      cohort, and 50% (95%CI, 9.5%-90.5%) in the PCPTCL-NOS cohort. The median duration 
      of response was 182 (45-323) weeks. The safety profile of mogamulizumab 
      monotherapy in the present cohort was comparable to the previous phase III, 
      randomized trial. The present study suggests that the efficacy and safety 
      profiles of mogamulizumab monotherapy as second-line therapy and beyond in a 
      real-world Japanese cohort were comparable to those in the previous phase III, 
      randomized trial.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Amagai, Ryo
AU  - Amagai R
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Kambayashi, Yumi
AU  - Kambayashi Y
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Ohuchi, Kentaro
AU  - Ohuchi K
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Furudate, Sadanori
AU  - Furudate S
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Hashimoto, Akira
AU  - Hashimoto A
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Asano, Yoshihide
AU  - Asano Y
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
FAU - Fujimura, Taku
AU  - Fujimura T
AUID- ORCID: 0000-0001-6809-5833
AD  - Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, 
      Japan.
LA  - eng
PT  - Journal Article
DEP - 20221001
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - YI437801BE (mogamulizumab)
RN  - 0 (Antibodies, Monoclonal, Humanized)
SB  - IM
MH  - Humans
MH  - Etoposide/therapeutic use
MH  - *Lymphoma, T-Cell, Cutaneous/drug therapy/pathology
MH  - *Mycosis Fungoides/drug therapy/pathology
MH  - Retrospective Studies
MH  - *Skin Neoplasms/drug therapy/pathology
MH  - Clinical Trials, Phase III as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Antibodies, Monoclonal, Humanized/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols
OTO - NOTNLM
OT  - CTCL
OT  - efficacy
OT  - etoposide
OT  - mogamulizumab
OT  - safety profile
EDAT- 2022/09/27 06:00
MHDA- 2022/11/05 06:00
CRDT- 2022/09/26 18:11
PHST- 2022/09/01 00:00 [revised]
PHST- 2022/07/30 00:00 [received]
PHST- 2022/09/21 00:00 [accepted]
PHST- 2022/09/27 06:00 [pubmed]
PHST- 2022/11/05 06:00 [medline]
PHST- 2022/09/26 18:11 [entrez]
AID - 10.1111/dth.15858 [doi]
PST - ppublish
SO  - Dermatol Ther. 2022 Nov;35(11):e15858. doi: 10.1111/dth.15858. Epub 2022 Oct 1.